One of the recurring themes at this year’s Endocrine Society ENDO 2026 meeting was choice: more treatment options for people living with acromegaly, and more long-term data to help patients and physicians decide among them. That was the focus of our conversation with Dr. Joanna Spencer-Segal, Associate Professor of Medicine and neuroendocrinologist at the University of Michigan, who joined us to talk through the newest results for CAM2029, an extended-release, once-monthly subcutaneous depot of octreotide delivered through a self-injection pen.
Some of the takeaways are particularly noteworthy:
- CAM 2029 shows no new safety signals over long-term use.
- Patients on CAM 2029 maintained 84% biochemical control at week 104.
- The pen device allows for self-administration at home, improving convenience.
- Biochemical control can be regained after treatment gaps, indicating formulation efficacy.
- Patient preference favors monthly injections over daily treatments.
Where things stand:
CAM2029 is already approved and marketed as Oczyesa® in the European Union and the United Kingdom for maintenance treatment of adults with acromegaly who have responded to and tolerated somatostatin analogs. In the United States, the picture is still unfolding. The FDA issued a Complete Response Letter in June 2026 for the US application (proposed name Oclaiz™). Importantly, that letter was tied to third-party manufacturing observations, not to the drug’s clinical efficacy or safety. Camurus has said it is working toward resubmission. As always with new therapies, US access remains an open question. Dr. Spencer-Segal noted it will be worth learning from colleagues in Europe about how access is playing out there. More information here
Stay tuned for more developments soon!
© 2026, J D Faccinetti. All rights reserved.